
|Articles|July 1, 2003
Expanding Possibilities
San Francisco - The expanding indications for the topical immune response modulator imiquimod (Aldara) may soon include treatment of superficial basal cell carcinoma (BCC), Mark Naylor, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
5



















